Spero Therapeutics (SPRO) EPS (Diluted) (QoQ) (2021 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) EPS (Diluted) (QoQ) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 209.95 Bn | 195.96 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.35 Bn | 177.17 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.62 Bn | 74.62 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.19 Bn | 56.00 Bn | 1.37 Bn |
| 6 | Moderna | 53.61 Bn | 48.47 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.75 Bn | 30.44 Bn | 992.69 Mn |
| 8 | Biogen | 31.58 Bn | 30.30 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.42 Bn | 29.42 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 67.53 Mn | 16.76 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.02% |
| Mar 31, 2026 | -124.80% |
| Dec 31, 2025 | 486.45% |
| Sep 30, 2025 | -331.26% |
| Jun 30, 2025 | 87.85% |
| Mar 31, 2025 | 33.37% |
| Dec 31, 2024 | -14.74% |
| Sep 30, 2024 | 1.07% |
| Jun 30, 2024 | -40.02% |
| Mar 31, 2024 | -124.47% |
| Dec 31, 2023 | 1,688.82% |
| Sep 30, 2023 | 73.16% |
| Jun 30, 2023 | 10.30% |
| Mar 31, 2023 | -135.45% |
| Dec 31, 2022 | 318.91% |
| Sep 30, 2022 | 58.68% |
| Jun 30, 2022 | 14.79% |
| Mar 31, 2022 | -4.11% |
| Dec 31, 2021 | -27.15% |
| Sep 30, 2021 | -12.23% |